Research programme: glaucoma gene therapy - Mayo Clinic/Oxford BioMedica

Drug Profile

Research programme: glaucoma gene therapy - Mayo Clinic/Oxford BioMedica

Alternative Names: Glaucoma-GT

Latest Information Update: 22 Apr 2014

Price : $50

At a glance

  • Originator Mayo Clinic
  • Developer Mayo Clinic; Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glaucoma

Most Recent Events

  • 22 Apr 2014 Preclinical development is ongoing in USA
  • 05 Sep 2012 Interim adverse events data from a preclinical trial in Glaucoma released by Oxford BioMedica
  • 31 Oct 2011 Preclinical trials in Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top